A deep dive into Abbott India Limited (ABBOTINDIA) — examining the financials, valuation picture, and who owns the stock.
Abbott India Revenue Trend
Top-line growth continued for Abbott India Limited, with FY2025 revenue reaching ₹6,409 Cr — a 5.1% increase over FY2024.
Abbott India Limited has compounded revenue at 10.8% over 10 years — good, consistent top-line expansion from ₹2,289 Cr to ₹6,409 Cr.
In terms of scale, Abbott India Limited's ₹6,409 Cr in annual revenue positions it as a mid-sized pharmaceuticals company.
The consistency stands out: 10 consecutive years of growth in top-line revenue.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹6,409 Cr | +5.1% |
| FY2024 | ₹6,097 Cr | +10.8% |
| FY2023 | ₹5,503 Cr | +10.1% |
| FY2022 | ₹4,996 Cr | +13.8% |
| FY2021 | ₹4,391 Cr | — |
View Abbott India Limited's full 10-year revenue trend with CAGR analysis →
Abbott India Profitability
The bottom line looked healthy: Abbott India Limited posted net profit of ₹1,414 Cr in FY2025, 17.8% above FY2024.
Net margin widened to 22.1% in FY2025 — an improvement from the 19.7% recorded in FY2024.
The diluted EPS figure moved up to ₹665.62 in FY2025, against ₹565.28 posted in FY2024.
Is Abbott India Undervalued
Using the P/E Ratio methodology, the calculated intrinsic value comes to ₹33,575.
Abbott India Limited shares are currently trading at ₹27,395.00.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹33,575 | 22.6% upside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Abbott India Limited with detailed assumptions →
Abbott India Shareholding Pattern
Promoters haven't moved — their 75.0% holding has been unchanged for 4 quarters.
FII ownership stands at 0.3%, up from the 0.2% recorded a year ago.
Domestic investors held 8.9% of the company as of March 2026, down year-over-year from 9.2%.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 75.0% | 0.3% | 8.9% | 15.8% |
| Dec 2025 | 75.0% | 0.2% | 9.0% | 15.8% |
| Sep 2025 | 75.0% | 0.2% | 9.1% | 15.8% |
| Jun 2025 | 75.0% | 0.2% | 9.2% | 15.7% |
Track quarterly shareholding changes for Abbott India Limited →
Abbott India Balance Sheet
Proportional view as of 13 Jul 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹59.17B (up 13.9% YoY from ₹51.93B).
Top categories: Other Assets (48.5%), Cash & ST Investments (27.5%), Inventories (14.9%).
Of the ₹59.17B in liabilities and equity, 71.5% is shareholder equity, 3.3% is interest-bearing debt, and 25.1% is operating liabilities. Over the year, debt is up 136.3% and equity is up 14.4%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 16.28B |
| Receivables | 3.80B |
| Inventories | 8.82B |
| Property, Plant & Equipment | 1.52B |
| Intangibles & Goodwill | 64.60M |
| Other Assets | 28.69B |
| Category | Value |
|---|---|
| Equity | 42.33B |
| Short-term Debt | 389.20M |
| Long-term Debt | 1.58B |
| Trade Payables | 10.58B |
| Other Liabilities | 4.30B |
Abbott India Stock Analysis
Pulling it all together, here's what the numbers say about Abbott India Limited (ABBOTINDIA) heading into the next fiscal year.
Revenue of ₹6,409 Cr in FY2025, up 5.1% year-over-year.
Long-term revenue has been compounding at 10.8% annually over 10 years.
The company is profitable, with a net margin of 22.1% and net income of ₹1,414 Cr.
The P/E Ratio model implies 22.6% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
For the complete 10-year financial history with interactive charts and growth analysis, explore Abbott India Limited's detailed profile on Craytheon.